𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Second malignant tumors after elective end of therapy for a first cancer in childhood: A multicenter study in Italy

✍ Scribed by Paolo Rosso; Benedetto Terracini; Thomas R. Fears; Momcilo Jankovic; Franca Fossati Bellani; Alberto Arrighini; Modesto Carli; Luca Cordero Di Montezemolo; Maria L. Garrè; Carlo Guazzelli; Giancarlo Izzi; Giuseppe Loiacono; Antonia Mancini; Paolo Tamaro; Anna M. Testi; Giuseppe Masera; Riccardo Haupt


Publisher
John Wiley and Sons
Year
1994
Tongue
French
Weight
689 KB
Volume
59
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

To evaluate the incidence of second malignant tumors in a cohort of subjects previously treated for childhood cancer, we analyzed data from the Off‐Therapy Registry (OTR) of the Italian Association of Pediatric Hematology/Oncology, which collects information on children treated for Hodgkin's disease, non‐Hodgkin's lymphoma, Wilms' tumor, acute lymphoblastic leukemia (ALL) and acute non‐lymphatic leukemia and who had been removed from treatment in the absence of clinical signs of disease, i.e. the off‐therapy stage. Second malignant tumors (SMT), diagnosed before December 31, 1988, were identified through a special enquiry to the 36 institutions cooperating in the registry. Observed cases were compared to expected numbers estimated from age‐ and sex‐specific incidence rates derived from the Cancer Registry of the Province of Varese. In a total of 3,310 study subjects, 27 SMTs have been registered. The Cumulative Risk (CR) of SMT was 2.9% 15 years after the end of treatment and the Standard Incidence Ratio (SIR) was 10.8. The ALL sub‐cohort had the highest risk of SMT (SIR 13.6) and 9 cases of CNS tumor occurred in this group (SIR 58.9). All 9 had received prophylactic cranial radiotherapy (CRT) and 5 had been treated on one protocol, characterized by low‐dose intrathecal methotrexate (IT MTX) given monthly for 2 years after CRT. The Off‐Therapy Registry has unique criteria for inclusion; direct comparisons with similar studies are therefore somewhat problematic. However, our data suggest that the risk of SMT in childhood ALL cancer survivors may be greater than previously reported, and that CNS tumors are the most common SMT in this group. The administration schedule of IT MTX may be an important risk factor. © 1994 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Early and late deaths after elective end
✍ Riccardo Haupt; M. Grazia Valsecchi; Daniela Silvestri; Paola De Lorenzo; Silvio 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 85 KB 👁 2 views

The first cohort of subjects treated for cancer during childhood is now entering adulthood, and it is necessary to determine whether treatment has been sufficient to completely eradicate the neoplastic clone, and whether the cancer itself or treatment-related toxicity may have increased the risk of

Incidence of second primary malignancies
✍ Corrado Magnani; Benedetto Terracini; Luca Cordero di Montezemolo; Gabriele Gall 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 534 KB

We have studied the frequency of second primary malignancies (SPM) among the 2,328 children registered in 1967-1989 at the Childhood Cancer Registry of Piedmont, the largest population-based childhood cancer registry in Southern Europe. Since the population of Piedmont is not sewed by a conventional

Prevalence of germline truncating mutati
✍ Timothy D. Shafman; Seth Levitz; Asa J. Nixon; Lor-Anne Gibans; Kim E. Nichols; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

Patients treated with conservative surgery and radiation therapy for early-stage breast cancer develop a contralateral breast cancer at a rate of approximately 0.75% per year. Ataxia-telangiectasia (AT) is an autosomal recessive disease that is characterized by increased sensitivity to ionizing radi

Concomitant chemo-radiotherapy and local
✍ Sylvie Guérin; Catherine Guibout; Akthar Shamsaldin; Marie-Gabrielle Dondon; Ibr 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 126 KB 👁 2 views

## Abstract Radiotherapy and chemotherapy are associated with an increased risk of a second malignant neoplasm (SMN) after a cancer during childhood. This study specified the dose‐effect relationship between radiotherapy, chemotherapy and the risk of a SMN, and investigated the effect of chemo‐radi

Second-line chemotherapy with fluorourac
✍ Aziz Zaanan; Mélanie Gauthier; David Malka; Christophe Locher; Jean-Marc Gornet; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB 👁 1 views

## Abstract ## BACKGROUND: Small bowel adenocarcinoma (SBA) is a rare tumor with poor prognosis. First‐line platinum‐based chemotherapy is active in patients with advanced SBA, but data regarding second‐line chemotherapy are lacking. The aim of this study was to evaluate the efficacy and tolerabil